Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure‐Response Analyses Underutilized?

por Jones, Aksana K., Salem, Ahmed Hamed, Freise, Kevin J.
Publicado 2019

Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY(®)) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study

por Jones, Aksana, Cohen-Barak, Orit, Radivojevic, Andrijana, Fiedler-Kelly, Jill
Publicado 2021

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials

por Jones, Aksana K., Ngaimisi, Eliford, Gopalakrishnan, Mathangi, Young, Malcolm A., Laffont, Celine M.
Publicado 2020

Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts

por Jones, Aksana, Saini, Jay, Kriel, Belinda, Via, Laura E., Cai, Yin, Allies, Devon, Hanna, Debra, Hermann, David, Loxton, Andre G., Walzl, Gerhard, Diacon, Andreas H., Romero, Klaus, Higashiyama, Ryo, Liu, Yongge, Berg, Alexander
Publicado 2022